Cancer screening (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cancer screening" in English language version.

refsWebsite

Global rank English rank

61nih.gov

4^th place

46doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

4handle.net

102^nd place

76^th place

3harvard.edu

18^th place

17^th place

2fda.gov

447^th place

338^th place

2nihr.ac.uk

low place

6,693^rd place

2web.archive.org

1^st place

1cancer.gov

1,684^th place

1,350^th place

1ourworldindata.org

2,263^rd place

1,687^th place

1kcl.ac.uk

3,833^rd place

2,331^st place

1europa.eu

68^th place

117^th place

1sapea.info

low place

1gov.uk

432^nd place

278^th place

1cancer.org

3,680^th place

2,918^th place

1uspreventiveservicestaskforce.org

low place

1crdha.ca

low place

1insideprecisionmedicine.com

low place

1wsj.com

79^th place

65^th place

cancer.gov

"What Is Cancer Screening?". National Cancer Institute. 2010-01-13.

cancer.org

"Tests for Pancreatic Cancer". www.cancer.org. Retrieved 2020-04-30.

crdha.ca

"Oral Cancer Screening". www.crdha.ca. Archived from the original on 11 September 2017. Retrieved 24 November 2017.

doi.org

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC (May 2019). "Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening". CA. 69 (3): 184–210. doi:10.3322/caac.21557. PMID 30875085.
Bobrowska A, Murton M, Seedat F, Visintin C, Mackie A, Steele R, Marshall J (May 2022). "Targeted screening in the UK: A narrow concept with broad application". The Lancet Regional Health. Europe. 16: 100353. doi:10.1016/j.lanepe.2022.100353. PMC 9038565. PMID 35492962.
Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. (March 2022). "Early detection of cancer". Science. 375 (6586): eaay9040. doi:10.1126/science.aay9040. PMID 35298272. S2CID 247521566.
Shepardson LB, Dean L (August 2020). "Current controversies in breast cancer screening". Seminars in Oncology. 47 (4): 177–181. doi:10.1053/j.seminoncol.2020.05.002. PMID 32513421. S2CID 219550403.
Miles A, Paschalidi A, Sharma N (September 2023). "The effect of numeric information about the likelihood of receiving a false negative or false positive result on people's attitudes towards colorectal cancer screening using faecal immunochemical testing (FIT)". Patient Education and Counseling. 114: 107857. doi:10.1016/j.pec.2023.107857. PMID 37348310.
SAPEA (2022-03-02). Improving Cancer Screening in the European Union. DE: Science Advice for Policy by European Academies (SAPEA). doi:10.26356/cancerscreening. ISBN 978-3-9823562-0-4.
Robra BP (2021). "Harms and Benefits of Cancer Screening". In Bauer AW, Hofheinz R, Utikal JS (eds.). Ethical Challenges in Cancer Diagnosis and Therapy. Recent Results in Cancer Research. Vol. 218. Cham: Springer International Publishing. pp. 85–104. doi:10.1007/978-3-030-63749-1_7. ISBN 978-3-030-63748-4. PMID 34019164. S2CID 235075529.
Hooshmand S, Reed WM, Suleiman ME, Brennan PC (March 2022). "A review of screening mammography: The benefits and radiation risks put into perspective". Journal of Medical Imaging and Radiation Sciences. 53 (1): 147–158. doi:10.1016/j.jmir.2021.12.002. PMID 34969620. S2CID 245529037.
Ratushnyak S, Hoogendoorn M, van Baal PH (December 2019). "Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained". American Journal of Preventive Medicine. 57 (6): 792–799. doi:10.1016/j.amepre.2019.07.027. hdl:1765/121569. PMID 31753260.
Petrova D, Garcia-Retamero R, Cokely ET (October 2015). "Understanding the Harms and Benefits of Cancer Screening: A Model of Factors That Shape Informed Decision Making". Medical Decision Making. 35 (7): 847–858. doi:10.1177/0272989X15587676. hdl:11858/00-001M-0000-0028-9E92-D. PMID 26044208. S2CID 13919922.
Abrahamsson L, Isheden G, Czene K, Humphreys K (February 2020). "Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies". Statistical Methods in Medical Research. 29 (2): 374–395. doi:10.1177/0962280219832901. PMID 30854935.
Chertow GM, Paltiel AD, Owen WF, Lazarus JM (June 1996). "Cost-effectiveness of cancer screening in end-stage renal disease". Archives of Internal Medicine. 156 (12): 1345–1350. doi:10.1001/archinte.1996.00440110117016. PMID 8651845.
"Catching cancer early: how research could help us improve". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2021-11-10. doi:10.3310/collection_48071. S2CID 244006179.
Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. (January 2020). "Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people". The Lancet. Psychiatry. 7 (1): 52–63. doi:10.1016/s2215-0366(19)30414-6. hdl:11577/3383784. PMID 31787585. S2CID 208535709.
Ross E, Maguire A, Donnelly M, Mairs A, Hall C, O'Reilly D (June 2020). "Does poor mental health explain socio-demographic gradients in breast cancer screening uptake? A population-based study". European Journal of Public Health. 30 (3): 396–401. doi:10.1093/eurpub/ckz220. PMID 31834366.
Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. (May 2020). "The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women". BMC Cancer. 20 (1): 452. doi:10.1186/s12885-020-06959-2. PMC 7240981. PMID 32434564.
Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. (September 2020). "Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women". Journal of Medical Screening. 27 (3): 130–137. doi:10.1177/0969141319887405. PMC 7645618. PMID 31791172.
Balata H, Harvey J, Barber PV, Colligan D, Duerden R, Elton P, et al. (August 2020). "Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD". Thorax. 75 (8): 655–660. doi:10.1136/thoraxjnl-2019-213584. PMID 32444437.
Waks AG, Winer EP (January 2019). "Breast Cancer Treatment: A Review". JAMA. 321 (3): 288–300. doi:10.1001/jama.2018.19323. PMID 30667505. S2CID 58580711.
Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, Straif K (June 2015). "Breast-cancer screening--viewpoint of the IARC Working Group". The New England Journal of Medicine. 372 (24): 2353–2358. doi:10.1056/NEJMsr1504363. PMID 26039523.
Nakamura Y, Kubota J, Nishimura Y, Nagata K, Nishimura M, Daino K, et al. (October 2022). "Brca1^L63X ^/+ rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation-induced mammary cancer". Cancer Science. 113 (10): 3362–3375. doi:10.1111/cas.15485. PMC 9530872. PMID 35851737.
European Commission. Directorate General for Research and Innovation., European Commission Group of Chief Scientific Advisors. (2022). Cancer screening in the European Union. LU: Publications Office. doi:10.2777/867180. ISBN 978-92-76-45603-2.
Wang W, Arcà E, Sinha A, Hartl K, Houwing N, Kothari S (August 2022). "Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review". Preventive Medicine Reports. 28: 101813. doi:10.1016/j.pmedr.2022.101813. PMC 9142642. PMID 35637896.
Lee HY, Li Q, Luo Y, Wang K, Hendrix S, Lee J, et al. (March 2021). "Is Pap Test Awareness Critical to Pap Test Uptake in Women Living in Rural Vietnam?". Asian Pacific Journal of Cancer Prevention. 22 (3): 903–908. doi:10.31557/APJCP.2021.22.3.903. PMC 8286658. PMID 33773556.
Qaseem A, Crandall CJ, Mustafa RA, Hicks LA, Wilt TJ, Forciea MA, et al. (November 2019). "Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians". Annals of Internal Medicine. 171 (9): 643–654. doi:10.7326/M19-0642. PMC 8152103. PMID 31683290.
Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. (May 2021). "Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 325 (19): 1965–1977. doi:10.1001/jama.2021.6238. PMID 34003218.
New screening pathways could improve NHS England's bowel cancer programme (Report). National Institute for Health Research. 2021-09-13. doi:10.3310/alert_47581.
Li SJ, Sharples LD, Benton SC, Blyuss O, Mathews C, Sasieni P, Duffy SW (September 2021). "Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies". Journal of Medical Screening. 28 (3): 277–285. doi:10.1177/0969141320980501. PMC 8366184. PMID 33342370.
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (May 2018). "Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 319 (18): 1914–1931. doi:10.1001/jama.2018.3712. PMID 29801018.
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S (September 2022). "Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches". Molecules. 27 (17): 5730. doi:10.3390/molecules27175730. PMC 9457814. PMID 36080493.
Welch HG, Albertsen PC (October 2009). "Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005". Journal of the National Cancer Institute. 101 (19): 1325–1329. doi:10.1093/jnci/djp278. PMC 2758309. PMID 19720969.
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. (February 2020). "Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial". The New England Journal of Medicine. 382 (6): 503–513. doi:10.1056/NEJMoa1911793. hdl:2066/216700. PMID 31995683.
O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SA (October 2018). "Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis". BMJ Open. 8 (10): e021611. doi:10.1136/bmjopen-2018-021611. PMC 6194454. PMID 30287668.
Colson YL, Shepard JO, Lennes IT (June 2021). "New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough". JAMA Surgery. 156 (6): 513–514. doi:10.1001/jamasurg.2021.0242. PMID 33687427. S2CID 232160050.
Banaei N, Foley A, Houghton JM, Sun Y, Kim B (November 2017). "Multiplex detection of pancreatic cancer biomarkers using a SERS-based immunoassay". Nanotechnology. 28 (45): 455101. Bibcode:2017Nanot..28S5101B. doi:10.1088/1361-6528/aa8e8c. PMID 28937361. S2CID 206086640.
Banaei N, Moshfegh J, Mohseni-Kabir A, Houghton JM, Sun Y, Kim B (January 2019). "Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips". RSC Advances. 9 (4): 1859–1868. Bibcode:2019RSCAd...9.1859B. doi:10.1039/c8ra08930b. PMC 9059745. PMID 35516124.
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P (October 2012). "Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (Suppl 7): vii33–vii40. doi:10.1093/annonc/mds224. PMID 22997452.
Stoita A, Penman ID, Williams DB (May 2011). "Review of screening for pancreatic cancer in high risk individuals". World Journal of Gastroenterology. 17 (19): 2365–2371. doi:10.3748/wjg.v17.i19.2365. PMC 3103788. PMID 21633635.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer". Lancet. 378 (9791): 607–620. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466.
Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A (March 2022). "US Cancer Screening Recommendations: Developments and the Impact of COVID-19". Medical Sciences. 10 (1): 16. doi:10.3390/medsci10010016. PMC 8949858. PMID 35323215.
Albert JM (July 2013). "Radiation risk from CT: implications for cancer screening". AJR. American Journal of Roentgenology. 201 (1): W81–W87. doi:10.2214/AJR.12.9226. PMID 23789701.
Lauenstein TC, Semelka RC (September 2006). "Emerging techniques: whole-body screening and staging with MRI". Journal of Magnetic Resonance Imaging. 24 (3): 489–498. doi:10.1002/jmri.20666. PMID 16888774.
Lumbreras B, Donat L, Hernández-Aguado I (April 2010). "Incidental findings in imaging diagnostic tests: a systematic review". The British Journal of Radiology. 83 (988): 276–289. doi:10.1259/bjr/98067945. PMC 3473456. PMID 20335439.
Etzioni R, Gulati R, Weiss NS (March 2022). "Multicancer Early Detection: Learning From the Past to Meet the Future". Journal of the National Cancer Institute. 114 (3): 349–352. doi:10.1093/jnci/djab168. PMC 8902333. PMID 34450655.
Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. (February 2023). "Liquid biopsies: the future of cancer early detection". Journal of Translational Medicine. 21 (1): 118. doi:10.1186/s12967-023-03960-8. PMC 9922467. PMID 36774504.
Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. (January 2023). "Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer". Scientific Reports. 13 (1): 1258. Bibcode:2023NatSR..13.1258S. doi:10.1038/s41598-022-25400-1. PMC 9870904. PMID 36690653.

europa.eu

data.europa.eu

European Commission. Directorate General for Research and Innovation., European Commission Group of Chief Scientific Advisors. (2022). Cancer screening in the European Union. LU: Publications Office. doi:10.2777/867180. ISBN 978-92-76-45603-2.

fda.gov

"Press Announcements - FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes". Food and Drug Administration. 2019-09-10.
Office of the Commissioner (2023-10-02). "FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types". FDA. Retrieved 2023-11-09.

gov.uk

"NHS bowel cancer screening (BCSP) programme". GOV.UK. 2021-03-17. Retrieved 2024-02-14.

handle.net

hdl.handle.net

Ratushnyak S, Hoogendoorn M, van Baal PH (December 2019). "Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained". American Journal of Preventive Medicine. 57 (6): 792–799. doi:10.1016/j.amepre.2019.07.027. hdl:1765/121569. PMID 31753260.
Petrova D, Garcia-Retamero R, Cokely ET (October 2015). "Understanding the Harms and Benefits of Cancer Screening: A Model of Factors That Shape Informed Decision Making". Medical Decision Making. 35 (7): 847–858. doi:10.1177/0272989X15587676. hdl:11858/00-001M-0000-0028-9E92-D. PMID 26044208. S2CID 13919922.
Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. (January 2020). "Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people". The Lancet. Psychiatry. 7 (1): 52–63. doi:10.1016/s2215-0366(19)30414-6. hdl:11577/3383784. PMID 31787585. S2CID 208535709.
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. (February 2020). "Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial". The New England Journal of Medicine. 382 (6): 503–513. doi:10.1056/NEJMoa1911793. hdl:2066/216700. PMID 31995683.

harvard.edu

ui.adsabs.harvard.edu

Banaei N, Foley A, Houghton JM, Sun Y, Kim B (November 2017). "Multiplex detection of pancreatic cancer biomarkers using a SERS-based immunoassay". Nanotechnology. 28 (45): 455101. Bibcode:2017Nanot..28S5101B. doi:10.1088/1361-6528/aa8e8c. PMID 28937361. S2CID 206086640.
Banaei N, Moshfegh J, Mohseni-Kabir A, Houghton JM, Sun Y, Kim B (January 2019). "Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips". RSC Advances. 9 (4): 1859–1868. Bibcode:2019RSCAd...9.1859B. doi:10.1039/c8ra08930b. PMC 9059745. PMID 35516124.
Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. (January 2023). "Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer". Scientific Reports. 13 (1): 1258. Bibcode:2023NatSR..13.1258S. doi:10.1038/s41598-022-25400-1. PMC 9870904. PMID 36690653.

insideprecisionmedicine.com

Branca M (2023-10-02). "First Blood Test for Dozens of Hereditary Cancers Approved by FDA". Inside Precision Medicine. Retrieved 2023-11-09.

kcl.ac.uk

kclpure.kcl.ac.uk

Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. (January 2020). "Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people". The Lancet. Psychiatry. 7 (1): 52–63. doi:10.1016/s2215-0366(19)30414-6. hdl:11577/3383784. PMID 31787585. S2CID 208535709.

nih.gov

pubmed.ncbi.nlm.nih.gov

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC (May 2019). "Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening". CA. 69 (3): 184–210. doi:10.3322/caac.21557. PMID 30875085.
Bobrowska A, Murton M, Seedat F, Visintin C, Mackie A, Steele R, Marshall J (May 2022). "Targeted screening in the UK: A narrow concept with broad application". The Lancet Regional Health. Europe. 16: 100353. doi:10.1016/j.lanepe.2022.100353. PMC 9038565. PMID 35492962.
Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. (March 2022). "Early detection of cancer". Science. 375 (6586): eaay9040. doi:10.1126/science.aay9040. PMID 35298272. S2CID 247521566.
Shepardson LB, Dean L (August 2020). "Current controversies in breast cancer screening". Seminars in Oncology. 47 (4): 177–181. doi:10.1053/j.seminoncol.2020.05.002. PMID 32513421. S2CID 219550403.
Miles A, Paschalidi A, Sharma N (September 2023). "The effect of numeric information about the likelihood of receiving a false negative or false positive result on people's attitudes towards colorectal cancer screening using faecal immunochemical testing (FIT)". Patient Education and Counseling. 114: 107857. doi:10.1016/j.pec.2023.107857. PMID 37348310.
Robra BP (2021). "Harms and Benefits of Cancer Screening". In Bauer AW, Hofheinz R, Utikal JS (eds.). Ethical Challenges in Cancer Diagnosis and Therapy. Recent Results in Cancer Research. Vol. 218. Cham: Springer International Publishing. pp. 85–104. doi:10.1007/978-3-030-63749-1_7. ISBN 978-3-030-63748-4. PMID 34019164. S2CID 235075529.
Hooshmand S, Reed WM, Suleiman ME, Brennan PC (March 2022). "A review of screening mammography: The benefits and radiation risks put into perspective". Journal of Medical Imaging and Radiation Sciences. 53 (1): 147–158. doi:10.1016/j.jmir.2021.12.002. PMID 34969620. S2CID 245529037.
Ratushnyak S, Hoogendoorn M, van Baal PH (December 2019). "Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained". American Journal of Preventive Medicine. 57 (6): 792–799. doi:10.1016/j.amepre.2019.07.027. hdl:1765/121569. PMID 31753260.
Petrova D, Garcia-Retamero R, Cokely ET (October 2015). "Understanding the Harms and Benefits of Cancer Screening: A Model of Factors That Shape Informed Decision Making". Medical Decision Making. 35 (7): 847–858. doi:10.1177/0272989X15587676. hdl:11858/00-001M-0000-0028-9E92-D. PMID 26044208. S2CID 13919922.
Abrahamsson L, Isheden G, Czene K, Humphreys K (February 2020). "Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies". Statistical Methods in Medical Research. 29 (2): 374–395. doi:10.1177/0962280219832901. PMID 30854935.
Chertow GM, Paltiel AD, Owen WF, Lazarus JM (June 1996). "Cost-effectiveness of cancer screening in end-stage renal disease". Archives of Internal Medicine. 156 (12): 1345–1350. doi:10.1001/archinte.1996.00440110117016. PMID 8651845.
Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. (January 2020). "Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people". The Lancet. Psychiatry. 7 (1): 52–63. doi:10.1016/s2215-0366(19)30414-6. hdl:11577/3383784. PMID 31787585. S2CID 208535709.
Ross E, Maguire A, Donnelly M, Mairs A, Hall C, O'Reilly D (June 2020). "Does poor mental health explain socio-demographic gradients in breast cancer screening uptake? A population-based study". European Journal of Public Health. 30 (3): 396–401. doi:10.1093/eurpub/ckz220. PMID 31834366.
Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. (May 2020). "The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women". BMC Cancer. 20 (1): 452. doi:10.1186/s12885-020-06959-2. PMC 7240981. PMID 32434564.
Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. (September 2020). "Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women". Journal of Medical Screening. 27 (3): 130–137. doi:10.1177/0969141319887405. PMC 7645618. PMID 31791172.
Balata H, Harvey J, Barber PV, Colligan D, Duerden R, Elton P, et al. (August 2020). "Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD". Thorax. 75 (8): 655–660. doi:10.1136/thoraxjnl-2019-213584. PMID 32444437.
Waks AG, Winer EP (January 2019). "Breast Cancer Treatment: A Review". JAMA. 321 (3): 288–300. doi:10.1001/jama.2018.19323. PMID 30667505. S2CID 58580711.
Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, Straif K (June 2015). "Breast-cancer screening--viewpoint of the IARC Working Group". The New England Journal of Medicine. 372 (24): 2353–2358. doi:10.1056/NEJMsr1504363. PMID 26039523.
Nakamura Y, Kubota J, Nishimura Y, Nagata K, Nishimura M, Daino K, et al. (October 2022). "Brca1^L63X ^/+ rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation-induced mammary cancer". Cancer Science. 113 (10): 3362–3375. doi:10.1111/cas.15485. PMC 9530872. PMID 35851737.
Wang W, Arcà E, Sinha A, Hartl K, Houwing N, Kothari S (August 2022). "Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review". Preventive Medicine Reports. 28: 101813. doi:10.1016/j.pmedr.2022.101813. PMC 9142642. PMID 35637896.
Lee HY, Li Q, Luo Y, Wang K, Hendrix S, Lee J, et al. (March 2021). "Is Pap Test Awareness Critical to Pap Test Uptake in Women Living in Rural Vietnam?". Asian Pacific Journal of Cancer Prevention. 22 (3): 903–908. doi:10.31557/APJCP.2021.22.3.903. PMC 8286658. PMID 33773556.
Qaseem A, Crandall CJ, Mustafa RA, Hicks LA, Wilt TJ, Forciea MA, et al. (November 2019). "Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians". Annals of Internal Medicine. 171 (9): 643–654. doi:10.7326/M19-0642. PMC 8152103. PMID 31683290.
Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. (May 2021). "Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 325 (19): 1965–1977. doi:10.1001/jama.2021.6238. PMID 34003218.
Li SJ, Sharples LD, Benton SC, Blyuss O, Mathews C, Sasieni P, Duffy SW (September 2021). "Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies". Journal of Medical Screening. 28 (3): 277–285. doi:10.1177/0969141320980501. PMC 8366184. PMID 33342370.
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (May 2018). "Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 319 (18): 1914–1931. doi:10.1001/jama.2018.3712. PMID 29801018.
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S (September 2022). "Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches". Molecules. 27 (17): 5730. doi:10.3390/molecules27175730. PMC 9457814. PMID 36080493.
Welch HG, Albertsen PC (October 2009). "Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005". Journal of the National Cancer Institute. 101 (19): 1325–1329. doi:10.1093/jnci/djp278. PMC 2758309. PMID 19720969.
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. (February 2020). "Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial". The New England Journal of Medicine. 382 (6): 503–513. doi:10.1056/NEJMoa1911793. hdl:2066/216700. PMID 31995683.
O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SA (October 2018). "Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis". BMJ Open. 8 (10): e021611. doi:10.1136/bmjopen-2018-021611. PMC 6194454. PMID 30287668.
Colson YL, Shepard JO, Lennes IT (June 2021). "New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough". JAMA Surgery. 156 (6): 513–514. doi:10.1001/jamasurg.2021.0242. PMID 33687427. S2CID 232160050.
Banaei N, Foley A, Houghton JM, Sun Y, Kim B (November 2017). "Multiplex detection of pancreatic cancer biomarkers using a SERS-based immunoassay". Nanotechnology. 28 (45): 455101. Bibcode:2017Nanot..28S5101B. doi:10.1088/1361-6528/aa8e8c. PMID 28937361. S2CID 206086640.
Banaei N, Moshfegh J, Mohseni-Kabir A, Houghton JM, Sun Y, Kim B (January 2019). "Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips". RSC Advances. 9 (4): 1859–1868. Bibcode:2019RSCAd...9.1859B. doi:10.1039/c8ra08930b. PMC 9059745. PMID 35516124.
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P (October 2012). "Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (Suppl 7): vii33–vii40. doi:10.1093/annonc/mds224. PMID 22997452.
Stoita A, Penman ID, Williams DB (May 2011). "Review of screening for pancreatic cancer in high risk individuals". World Journal of Gastroenterology. 17 (19): 2365–2371. doi:10.3748/wjg.v17.i19.2365. PMC 3103788. PMID 21633635.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer". Lancet. 378 (9791): 607–620. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466.
Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A (March 2022). "US Cancer Screening Recommendations: Developments and the Impact of COVID-19". Medical Sciences. 10 (1): 16. doi:10.3390/medsci10010016. PMC 8949858. PMID 35323215.
Albert JM (July 2013). "Radiation risk from CT: implications for cancer screening". AJR. American Journal of Roentgenology. 201 (1): W81–W87. doi:10.2214/AJR.12.9226. PMID 23789701.
Lauenstein TC, Semelka RC (September 2006). "Emerging techniques: whole-body screening and staging with MRI". Journal of Magnetic Resonance Imaging. 24 (3): 489–498. doi:10.1002/jmri.20666. PMID 16888774.
Lumbreras B, Donat L, Hernández-Aguado I (April 2010). "Incidental findings in imaging diagnostic tests: a systematic review". The British Journal of Radiology. 83 (988): 276–289. doi:10.1259/bjr/98067945. PMC 3473456. PMID 20335439.
Etzioni R, Gulati R, Weiss NS (March 2022). "Multicancer Early Detection: Learning From the Past to Meet the Future". Journal of the National Cancer Institute. 114 (3): 349–352. doi:10.1093/jnci/djab168. PMC 8902333. PMID 34450655.
Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. (February 2023). "Liquid biopsies: the future of cancer early detection". Journal of Translational Medicine. 21 (1): 118. doi:10.1186/s12967-023-03960-8. PMC 9922467. PMID 36774504.
Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. (January 2023). "Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer". Scientific Reports. 13 (1): 1258. Bibcode:2023NatSR..13.1258S. doi:10.1038/s41598-022-25400-1. PMC 9870904. PMID 36690653.

ncbi.nlm.nih.gov

Bobrowska A, Murton M, Seedat F, Visintin C, Mackie A, Steele R, Marshall J (May 2022). "Targeted screening in the UK: A narrow concept with broad application". The Lancet Regional Health. Europe. 16: 100353. doi:10.1016/j.lanepe.2022.100353. PMC 9038565. PMID 35492962.
Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. (May 2020). "The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women". BMC Cancer. 20 (1): 452. doi:10.1186/s12885-020-06959-2. PMC 7240981. PMID 32434564.
Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. (September 2020). "Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women". Journal of Medical Screening. 27 (3): 130–137. doi:10.1177/0969141319887405. PMC 7645618. PMID 31791172.
Nakamura Y, Kubota J, Nishimura Y, Nagata K, Nishimura M, Daino K, et al. (October 2022). "Brca1^L63X ^/+ rat is a novel model of human BRCA1 deficiency displaying susceptibility to radiation-induced mammary cancer". Cancer Science. 113 (10): 3362–3375. doi:10.1111/cas.15485. PMC 9530872. PMID 35851737.
Wang W, Arcà E, Sinha A, Hartl K, Houwing N, Kothari S (August 2022). "Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review". Preventive Medicine Reports. 28: 101813. doi:10.1016/j.pmedr.2022.101813. PMC 9142642. PMID 35637896.
Lee HY, Li Q, Luo Y, Wang K, Hendrix S, Lee J, et al. (March 2021). "Is Pap Test Awareness Critical to Pap Test Uptake in Women Living in Rural Vietnam?". Asian Pacific Journal of Cancer Prevention. 22 (3): 903–908. doi:10.31557/APJCP.2021.22.3.903. PMC 8286658. PMID 33773556.
Qaseem A, Crandall CJ, Mustafa RA, Hicks LA, Wilt TJ, Forciea MA, et al. (November 2019). "Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians". Annals of Internal Medicine. 171 (9): 643–654. doi:10.7326/M19-0642. PMC 8152103. PMID 31683290.
Li SJ, Sharples LD, Benton SC, Blyuss O, Mathews C, Sasieni P, Duffy SW (September 2021). "Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies". Journal of Medical Screening. 28 (3): 277–285. doi:10.1177/0969141320980501. PMC 8366184. PMID 33342370.
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S (September 2022). "Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches". Molecules. 27 (17): 5730. doi:10.3390/molecules27175730. PMC 9457814. PMID 36080493.
Welch HG, Albertsen PC (October 2009). "Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005". Journal of the National Cancer Institute. 101 (19): 1325–1329. doi:10.1093/jnci/djp278. PMC 2758309. PMID 19720969.
O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SA (October 2018). "Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis". BMJ Open. 8 (10): e021611. doi:10.1136/bmjopen-2018-021611. PMC 6194454. PMID 30287668.
Banaei N, Moshfegh J, Mohseni-Kabir A, Houghton JM, Sun Y, Kim B (January 2019). "Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips". RSC Advances. 9 (4): 1859–1868. Bibcode:2019RSCAd...9.1859B. doi:10.1039/c8ra08930b. PMC 9059745. PMID 35516124.
Stoita A, Penman ID, Williams DB (May 2011). "Review of screening for pancreatic cancer in high risk individuals". World Journal of Gastroenterology. 17 (19): 2365–2371. doi:10.3748/wjg.v17.i19.2365. PMC 3103788. PMID 21633635.
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (August 2011). "Pancreatic cancer". Lancet. 378 (9791): 607–620. doi:10.1016/S0140-6736(10)62307-0. PMC 3062508. PMID 21620466.
Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A (March 2022). "US Cancer Screening Recommendations: Developments and the Impact of COVID-19". Medical Sciences. 10 (1): 16. doi:10.3390/medsci10010016. PMC 8949858. PMID 35323215.
Lumbreras B, Donat L, Hernández-Aguado I (April 2010). "Incidental findings in imaging diagnostic tests: a systematic review". The British Journal of Radiology. 83 (988): 276–289. doi:10.1259/bjr/98067945. PMC 3473456. PMID 20335439.
Etzioni R, Gulati R, Weiss NS (March 2022). "Multicancer Early Detection: Learning From the Past to Meet the Future". Journal of the National Cancer Institute. 114 (3): 349–352. doi:10.1093/jnci/djab168. PMC 8902333. PMID 34450655.
Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. (February 2023). "Liquid biopsies: the future of cancer early detection". Journal of Translational Medicine. 21 (1): 118. doi:10.1186/s12967-023-03960-8. PMC 9922467. PMID 36774504.
Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. (January 2023). "Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer". Scientific Reports. 13 (1): 1258. Bibcode:2023NatSR..13.1258S. doi:10.1038/s41598-022-25400-1. PMC 9870904. PMID 36690653.

nihr.ac.uk

evidence.nihr.ac.uk

"Catching cancer early: how research could help us improve". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2021-11-10. doi:10.3310/collection_48071. S2CID 244006179.
New screening pathways could improve NHS England's bowel cancer programme (Report). National Institute for Health Research. 2021-09-13. doi:10.3310/alert_47581.

ourworldindata.org

Roser M (December 7, 2021). "Causes of death globally: what do people die from?". Our World in Data.

sapea.info

"Improving cancer screening in the European Union". Scientific Advice for Policy by European Academies. 2 March 2022. Archived from the original on 2022-03-01. Retrieved 10 March 2022.

semanticscholar.org

api.semanticscholar.org

Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. (March 2022). "Early detection of cancer". Science. 375 (6586): eaay9040. doi:10.1126/science.aay9040. PMID 35298272. S2CID 247521566.
Shepardson LB, Dean L (August 2020). "Current controversies in breast cancer screening". Seminars in Oncology. 47 (4): 177–181. doi:10.1053/j.seminoncol.2020.05.002. PMID 32513421. S2CID 219550403.
Robra BP (2021). "Harms and Benefits of Cancer Screening". In Bauer AW, Hofheinz R, Utikal JS (eds.). Ethical Challenges in Cancer Diagnosis and Therapy. Recent Results in Cancer Research. Vol. 218. Cham: Springer International Publishing. pp. 85–104. doi:10.1007/978-3-030-63749-1_7. ISBN 978-3-030-63748-4. PMID 34019164. S2CID 235075529.
Hooshmand S, Reed WM, Suleiman ME, Brennan PC (March 2022). "A review of screening mammography: The benefits and radiation risks put into perspective". Journal of Medical Imaging and Radiation Sciences. 53 (1): 147–158. doi:10.1016/j.jmir.2021.12.002. PMID 34969620. S2CID 245529037.
Petrova D, Garcia-Retamero R, Cokely ET (October 2015). "Understanding the Harms and Benefits of Cancer Screening: A Model of Factors That Shape Informed Decision Making". Medical Decision Making. 35 (7): 847–858. doi:10.1177/0272989X15587676. hdl:11858/00-001M-0000-0028-9E92-D. PMID 26044208. S2CID 13919922.
"Catching cancer early: how research could help us improve". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2021-11-10. doi:10.3310/collection_48071. S2CID 244006179.
Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. (January 2020). "Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people". The Lancet. Psychiatry. 7 (1): 52–63. doi:10.1016/s2215-0366(19)30414-6. hdl:11577/3383784. PMID 31787585. S2CID 208535709.
Waks AG, Winer EP (January 2019). "Breast Cancer Treatment: A Review". JAMA. 321 (3): 288–300. doi:10.1001/jama.2018.19323. PMID 30667505. S2CID 58580711.
Colson YL, Shepard JO, Lennes IT (June 2021). "New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough". JAMA Surgery. 156 (6): 513–514. doi:10.1001/jamasurg.2021.0242. PMID 33687427. S2CID 232160050.
Banaei N, Foley A, Houghton JM, Sun Y, Kim B (November 2017). "Multiplex detection of pancreatic cancer biomarkers using a SERS-based immunoassay". Nanotechnology. 28 (45): 455101. Bibcode:2017Nanot..28S5101B. doi:10.1088/1361-6528/aa8e8c. PMID 28937361. S2CID 206086640.

uspreventiveservicestaskforce.org

"Final Recommendation Statement: Oral Cancer: Screening - US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. November 2013. Retrieved 23 November 2017.

web.archive.org

"Improving cancer screening in the European Union". Scientific Advice for Policy by European Academies. 2 March 2022. Archived from the original on 2022-03-01. Retrieved 10 March 2022.
"Oral Cancer Screening". www.crdha.ca. Archived from the original on 11 September 2017. Retrieved 24 November 2017.

wsj.com

Janin A (2023-10-25). "This $1,000 Test Finds Signs of Cancer in Your Blood". WSJ. Retrieved 2023-11-09.